Intellia Therapeutics Lands Up to $400 Million in Non-Dilutive OrbiMed Term Loan

Intellia Therapeutics (NTLA ) entered into a non-dilutive senior secured term loan facility with healthcare investment firm OrbiMed on September 4, 2026, the gene editing company announced. The facility provides for up to $400 million, with $75 million funded upfront and an additional $325 million tied to milestones.

The Cambridge, Massachusetts-based company described the transaction as providing greater financial and operational flexibility as it advances toward several key milestones, including a planned U.S. approval and commercial launch of lonvoguran ziclumeran (lonvo-z) as a one-time treatment for patients with hereditary angioedema (HAE).

Under the agreement, an initial term loan of $75 million was funded at closing. Five additional tranches totaling up to $225 million can be drawn at Intellia’s option, subject to the company’s achievement of specified milestones related primarily to lonvo-z. A further $100 million is available subject to mutual agreement between the parties during the five-year term of the agreement.

“Lonvo-z has the potential to transform the treatment paradigm for people living with HAE as well as the future capital needs of our company,” said Edward Dulac, Intellia’s Chief Financial Officer. “This non-dilutive financing enables us to more freely execute our plan to successfully launch lonvo-z in HAE, advance nexiguran ziclumeran through multiple important milestones in transthyretin amyloidosis and create value through our early pipeline development efforts.”

“OrbiMed is proud to partner with Intellia Therapeutics, a well-recognized leader in the in vivo gene editing revolution,” said Matthew Rizzo, General Partner at OrbiMed. “We are looking forward to supporting the team as it approaches a number of exciting and transformational milestones.”

TD Cowen acted as exclusive financial advisor to Intellia on the transaction. Goodwin Procter LLP acted as legal advisor to Intellia, and Covington & Burling LLP acted as legal advisor to OrbiMed.

Additional details of the loan agreement will be filed with the Securities and Exchange Commission on a Current Report on Form 8-K, the company said.

Facility Follows Phase 3 Data and Rolling BLA Submission

The loan follows a series of regulatory and clinical steps for lonvo-z this year. On April 27, 2026, Intellia announced it had initiated a rolling submission of a biologics license application (BLA) to the U.S. Food and Drug Administration seeking approval of lonvo-z, formerly known as NTLA-2002, for HAE. The rolling submission is being conducted pursuant to the Regenerative Medicine Advanced Therapy (RMAT) designation the FDA granted to the candidate, which allows Intellia to submit portions of the application on an ongoing basis. The company anticipates completing the submission in the second half of 2026 and, if approved, plans to launch lonvo-z commercially in the first half of 2027. In its second-quarter 2026 financial results, published August 6, 2026, the company said it expects the FDA to accept the BLA in the second half of 2026.

Lonvo-z is an in vivo CRISPR gene editing candidate designed to permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene with a single dose administered in an outpatient setting. The company said the candidate has received five regulatory designations: Orphan Drug and RMAT designations from the FDA, the Innovation Passport from the U.K. Medicines and Healthcare products Regulatory Agency, Priority Medicines (PRIME) designation from the European Medicines Agency, and Orphan Drug Designation from the European Commission.

In April, Intellia reported positive topline results from the global Phase 3 HAELO clinical trial of lonvo-z in HAE, with additional data presented in June 2026 at the European Academy of Allergy & Clinical Immunology Annual Congress and published in the New England Journal of Medicine. According to the company, the trial met its primary endpoint: for the six-month efficacy evaluation period spanning weeks 5 to 28, a one-time infusion of lonvo-z reduced attacks by 87% versus placebo, with a mean monthly attack rate of 0.26 in the lonvo-z arm compared with 2.10 in the placebo arm. The trial also met all key secondary endpoints with statistical significance, including 62% of patients in the lonvo-z arm entirely attack free and therapy free during the six-month evaluation period, compared with 11% in the placebo arm.

Intellia reported that all patients who received lonvo-z at baseline or in crossover after week 28 remained free from long-term prophylaxis therapy as of the February 10, 2026 data cutoff. The most common treatment emergent adverse events were infusion-related reactions, headache, fatigue, back pain, and upper respiratory tract infection; all were mild or moderate, and no serious adverse events were observed in the lonvo-z arm, the company said.

Hereditary angioedema is a rare, genetic disease characterized by severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body. According to Intellia, an estimated one in 50,000 people are affected by HAE, and current treatment options often include lifelong therapies that may require chronic intravenous or subcutaneous administration as often as twice per week, or daily oral administration.

Nex-Z Program and Cash Position

The second program named in the financing announcement, nexiguran ziclumeran (nex-z), is an investigational in vivo CRISPR-based candidate designed to inactivate the TTR gene in the liver, preventing production of transthyretin protein. Intellia leads development and commercialization of nex-z in collaboration with Regeneron Pharmaceuticals (REGN ). The company has advanced enrollment in its MAGNITUDE and MAGNITUDE-2 Phase 3 trials of nex-z in ATTR amyloidosis with cardiomyopathy and hereditary ATTR amyloidosis with polyneuropathy, respectively, and said it remains on track to complete patient enrollment in MAGNITUDE-2 in the second half of 2026.

Intellia entered the facility from what it described as a strengthened balance sheet. Cash, cash equivalents and marketable securities were $628.4 million as of June 30, 2026, compared with $605.1 million as of December 31, 2025, according to its second-quarter report. In April 2026, the company completed an underwritten public offering of its common stock resulting in approximately $195 million in net proceeds. Intellia has said its existing cash resources are expected to fund operations at least into 2028, guidance that excludes all potential commercial revenues from lonvo-z.